Mike Brown (Q-Squared Solutions; GA, USA), discusses the different tests required when looking at a potential therapeutic and what aspects of biology need to be considered. He also explores how important early engagement with the FDA and clinical trial partners are.
The future of individualized medicine: intensified decentralized biotherapeutic production in combination with state-of-the-art diagnostics of the next generation
In this editorial the future of individualized medicine is reviewed, focusing on the decentralization of biotherapeutic production in combination with state-of-the-art diagnostics of the next generation.
In this interview, John Kellie (GSK, PA, USA) discusses the technologies that he uses on a regular basis. He explains how large molecule bioanalysis influences downstream drug development and his future outlook on where the field will be in 5–10 years’ time.
A team from the University of Toronto (ON, Canada) has developed a method to produce geometric isoforms of drugs, potentially leading to improved efficiency.